Given the potential significance of the Yao study for GPC3 as a novel prognostic and predictive marker in pancreatic adenocarcinoma, we wanted to see if we could replicate their GPC3 results in pancreatic cancers in our Canadian patient population. This evidence concerns the gene GPC3 and familial pancreatic carcinoma.